Genmab — Marts 2019

[AaBforever]

Det går den vej hønsene skraber...som vi siger heroppe...nedad!!

[Solsen]

JW siger, at de er ved at lave et $40-50 bn co

[nohope]

Kan han så ikke udbetale et forskud ? F.eks. på 50 % ?

[peter12]

Der er vist ikke så meget nyt ? https://www.cancertherapyadvisor.com/home/news/conference-coverage/society-of-gynecologic-oncology-sgo/sgo-2019/cervical-cancer-tisotumab-vedotin-promising-early-treatment-results/

[peter12]

Lidt mere om TV https://www.youtube.com/watch?v=tAvbJCXJu74

[peter12]

Eller har ORR øget fra 26.5% til 32% i cervical ?

[transalp]

Go morgen:)

[Helge_LarsenPI-redaktør]

God morgen.

[polle1]

God morgen og god dag

[Helge_LarsenPI-redaktør]

Ses vi i Aarhus? https://billetto.dk/e/investor-battle-helge-larsen-vs-hans-henrik-nielsen-billetter-335559?fbclid=IwAR3IGL5yJcMh_NTHXjVvR_wn82lJ1zoaj6J-t7ykjzqm7flV2T7hX6c7MhI

[E_L]

@peter12 I thinks TV response rate is the same as at ESMO ( investigator (INV)-assessed response rate of 32% (26% confirmed) ) but duration went up from 4.9 months to 5.5 months

[E_L]

ESMO 18 https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/A-Phase-IIa-study-of-tisotumab-vedotin-in-patients-with-previously-treated-recurrent-or-metastatic-cervical-cancer-updated-analysis-of-full-cervical-expansion-cohort

[peter12]

Ok thx

[StockBull]

@iboge. Tror vi skal være glade for 6,375USD per dag for Februar for salget i USD begynder ikke at rykke igen før 1st line begynder at sælge. 4, 3 and 2 linie er slaget jo allerede ved at flade ud.

[StockBull]

så mit bud for imorgens tal er 121

[iboge]

Jan indikerede ved q&a ved årsregnskab, at de første 14 dage af februar var de hidtil bedste. Jvf. jkj 18/3 09.27. Derfor håber jeg, at salget for februar bliver rigtig gode.

[E_L]

Roche, AbbVie forced to slam brakes on myeloma studies of star drug Venclexta after researchers flag higher risk of death https://endpts.com/roche-abbvie-slam-the-brakes-on-myeloma-studies-of-star-drug-venclexta-after-researchers-flag-higher-risk-of-death/

[E_L]

This is the one with Dara https://clinicaltrials.gov/ct2/show/NCT03701321?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+arzerra+OR+darzalex&lupd_s=03%2F17%2F2019&rank=1

[Bulder]

Helt præcist: ... the IMS data, the first 2 weeks of February look very, very good in the U.S.

[E_L]

a bit surprised
they extend this Leukemia study with Ofatumumab? https://clinicaltrials.gov/ct2/history/NCT02199184?A=12&B=13&C=merged